Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.
Abraham JE, O'Connor LO, Grybowicz L, Alba KP, Dayimu A, Demiris N, Harvey C, Drewett LM, Lucey R, Fulton A, Roberts AN, Worley JR, Chhabra MA, Qian W, Brown J, Hardy R, Vallier AL, Chan S, Cidon MEU, Sherwin E, Chakrabarti A, Sadler C, Barnes J, Persic M, Smith S, Raj S, Borley A, Braybrooke JP, Staples E, Scott LC, Palmer CA, Moody M, Churn MJ, Pilger D, Zagnoli-Vieira G, Wijnhoven PWG, Mukesh MB, Roylance RR, Schouten PC, Levitt NC, McAdam K, Armstrong AC, Copson ER, McMurtry E, Galbraith S, Tischkowitz M, Provenzano E, O'Connor MJ, Earl HM; PARTNER Trial Group. Abraham JE, et al. Among authors: schouten pc. Nat Commun. 2025 May 13;16(1):4269. doi: 10.1038/s41467-025-59151-0. Nat Commun. 2025. PMID: 40360463 Free PMC article. Clinical Trial.
Selective changes in vasopressin neurons and astrocytes in the suprachiasmatic nucleus of Prader-Willi syndrome subjects.
Correa-da-Silva F, Berkhout JB, Schouten P, Sinnema M, Stumpel CTRM, Curfs LMG, Höybye C, Mahfouz A, Meijer OC, Pereira AM, Fliers E, Swaab DF, Kalsbeek A, Yi CX. Correa-da-Silva F, et al. Among authors: schouten p. J Neuroendocrinol. 2025 May;37(5):e70015. doi: 10.1111/jne.70015. Epub 2025 Mar 8. J Neuroendocrinol. 2025. PMID: 40055943 Free PMC article.
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.
Marmé F, Krieghoff-Henning EI, Kiehl L, Wies C, Hauke J, Hahnen E, Harter P, Schouten PC, Brodkorb T, Kayali M, Heitz F, Zamagni C, González-Martin A, Treilleux I, Kommoss S, Prieske K, Gaiser T, Fröhling S, Ray-Coquard I, Pujade-Lauraine E, Brinker TJ. Marmé F, et al. Among authors: schouten pc. Eur J Cancer. 2025 Feb 5;216:115199. doi: 10.1016/j.ejca.2024.115199. Epub 2024 Dec 26. Eur J Cancer. 2025. PMID: 39742559 Free article.
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC, Schmidt S, Becker K, Thiele H, Nürnberg P, Richters L, Ernst C, Treilleux I, Medioni J, Heitz F, Pisano C, Garcia Y, Petru E, Hietanen S, Colombo N, Vergote I, Nagao S, Linn SC, Pujade-Lauraine E, Ray-Coquard I, Harter P, Hahnen E, Schmutzler RK. Schouten PC, et al. JAMA Netw Open. 2024 Apr 1;7(4):e245552. doi: 10.1001/jamanetworkopen.2024.5552. JAMA Netw Open. 2024. PMID: 38592722 Free PMC article. Clinical Trial.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, Drewett LM, Lucey R, Fulton A, Roberts AN, Worley JR, Chhabra A, Qian W, Vallier AL, Hardy RM, Chan S, Hickish T, Tripathi D, Venkitaraman R, Persic M, Aslam S, Glassman D, Raj S, Borley A, Braybrooke JP, Sutherland S, Staples E, Scott LC, Davies M, Palmer CA, Moody M, Churn MJ, Newby JC, Mukesh MB, Chakrabarti A, Roylance RR, Schouten PC, Levitt NC, McAdam K, Armstrong AC, Copson ER, McMurtry E, Tischkowitz M, Provenzano E, Earl HM. Abraham JE, et al. Among authors: schouten pc. Nature. 2024 May;629(8014):1142-1148. doi: 10.1038/s41586-024-07384-2. Epub 2024 Apr 8. Nature. 2024. PMID: 38588696 Free PMC article. Clinical Trial.
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y, Dackus GMHE, Rosenberg EH, Cornelissen S, de Boo LW, Broeks A, Brugman W, Chan TWS, van Diest PJ, Hauptmann M, Ter Hoeve ND, Isaeva OI, de Jong VMT, Jóźwiak K, Kluin RJC, Kok M, Koop E, Nederlof PM, Opdam M, Schouten PC, Siesling S, van Steenis C, Voogd AC, Vreuls W, Salgado RF, Linn SC, Schmidt MK. Wang Y, et al. Among authors: schouten pc. BMC Med. 2024 Jan 9;22(1):9. doi: 10.1186/s12916-023-03233-7. BMC Med. 2024. PMID: 38191387 Free PMC article.
The ISMRM Open Science Initiative for Perfusion Imaging (OSIPI): Results from the OSIPI-Dynamic Contrast-Enhanced challenge.
Shalom ES, Kim H, van der Heijden RA, Ahmed Z, Patel R, Hormuth DA 2nd, DiCarlo JC, Yankeelov TE, Sisco NJ, Dortch RD, Stokes AM, Inglese M, Grech-Sollars M, Toschi N, Sahoo P, Singh A, Verma SK, Rathore DK, Kazerouni AS, Partridge SC, LoCastro E, Paudyal R, Wolansky IA, Shukla-Dave A, Schouten P, Gurney-Champion OJ, Jiřík R, Macíček O, Bartoš M, Vitouš J, Das AB, Kim SG, Bokacheva L, Mikheev A, Rusinek H, Berks M, Hubbard Cristinacce PL, Little RA, Cheung S, O'Connor JPB, Parker GJM, Moloney B, LaViolette PS, Bobholz S, Duenweg S, Virostko J, Laue HO, Sung K, Nabavizadeh A, Saligheh Rad H, Hu LS, Sourbron S, Bell LC, Fathi Kazerooni A. Shalom ES, et al. Among authors: schouten p. Magn Reson Med. 2024 May;91(5):1803-1821. doi: 10.1002/mrm.29909. Epub 2023 Dec 19. Magn Reson Med. 2024. PMID: 38115695 Free article.
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F, Marth C, Henry S, Reuss A, Cibula D, Gaba Garcia L, Colombo N, Schmalfeld B, de Gregorio N, Wimberger P, Hasenburg A, Sehouli J, Gropp-Meier M, Schouten PC, Hahnen E, Hauke J, Polleis S, Harter P. Heitz F, et al. Among authors: schouten pc. Int J Gynecol Cancer. 2023 Dec 4;33(12):1966-1969. doi: 10.1136/ijgc-2023-004944. Int J Gynecol Cancer. 2023. PMID: 37935524 Free article. Clinical Trial.
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
van Wagensveld L, van Baal JOAM, Timmermans M, Gaillard D, Borghuis L, Coffelt SB, Rosenberg EH, Lok CAR, Nijman HW, Kooreman LFS, Sanders J, de Bruijn M, Wessels LFA, van der Wiel R, Rausch C, Broeks A, Kruitwagen RFPM, van der Aa MA, Sonke GS, Schouten PC, Van de Vijver KK, Horlings HM. van Wagensveld L, et al. Among authors: schouten pc. Cancers (Basel). 2022 Dec 2;14(23):5965. doi: 10.3390/cancers14235965. Cancers (Basel). 2022. PMID: 36497449 Free PMC article.
65 results